Array BioPharma (ARRY) PT Raised to $24 at Jefferies
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $8.54 +6.75%
Rating Summary:
19 Buy, 13 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 18 | Down: 12 | New: 24
Rating Summary:
19 Buy, 13 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 18 | Down: 12 | New: 24
Join SI Premium – FREE
Jefferies analyst Eun Yang raised the price target on Array BioPharma (NASDAQ: ARRY) to $24.00 (from $21.00) while maintaining a Buy rating.
Yang notes the company narrowed its Q2 net loss of strong Braftovi/Mektovi sales.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Incyte (INCY) PT Raised to $105 at Truist Securities
- Regenxbio Inc. (RGNX) PT Raised to $18 at Leerink
- Progyny (PGNY) PT Raised to $33 at Truist Securities
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
